Tiziana Life Sciences secures FDA Fast Track status for MS therapy intranasal foralumabProactive Investors • 07/24/24
Tiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapyProactive Investors • 06/26/24
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with ForalumabGlobeNewsWire • 06/26/24
Tiziana Life Sciences seeks FDA Fast Track Designation for foralumab in MS treatmentProactive Investors • 06/11/24
Tiziana Life Sciences reports qualitative improvement in MS patients treated with lead assetProactive Investors • 06/06/24
Tiziana Life Sciences seeks funding from ALS Association for intranasal foralumab trialProactive Investors • 06/04/24
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis ResearchGlobeNewsWire • 05/30/24
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal ForalumabGlobeNewsWire • 05/13/24
Tiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patientsProactive Investors • 04/25/24
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal ForalumabGlobeNewsWire • 04/25/24
Tiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access ProgramProactive Investors • 04/23/24
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access ProgramGlobeNewsWire • 04/23/24
Tiziana Life Sciences reports additional positive results from Multiple Sclerosis programProactive Investors • 04/22/24
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access ProgramGlobeNewsWire • 04/22/24
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®GlobeNewsWire • 04/19/24
Tiziana Life Sciences says foralumab shows promise in stabilizing certain types of MSProactive Investors • 04/18/24
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of NeurologyGlobeNewsWire • 04/18/24